Projects overview

Sort by


Toggle all information

VITAL | Vaccines and Infectious Diseases in the Ageing PopuLation

01-01-2019

-

31-12-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-12-two-stage
IMI2-2017-12-05 Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations

TransQST | Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030

01-01-2017

-

31-08-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-01 Development of Quantitative System Toxicology (QST) approaches to improve the understanding of the safety of new medicines

LITMUS | Liver Investigation: Testing Marker Utility in Steatohepatitis

01-11-2017

-

29-02-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-05 IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ACROSS THE SPECTRUM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

RESCEU | REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019

01-01-2017

-

30-09-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-02 Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences

ITCC-P4 | ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

01-01-2017

-

31-12-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER

ADAPTED | Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

01-10-2016

-

30-09-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-06 From ApoE biology to validated Alzheimer’s disease targets

EBODAC | Communication strategy and tools for optimizing the impact of Ebola vaccination deployment – Sofia ref.: 115847

01-12-2014

-

30-11-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2014-02-single-stage
IMI2-2014-02-04 Deployment and compliance of vaccination regimens

NGN-PET | Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

01-04-2017

-

31-03-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-03 PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN

PEVIA | PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

01-06-2017

-

31-05-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-08-single-stage
IMI2-2015-08-01 Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

IM2PACT | Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain

01-01-2019

-

31-12-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-12-two-stage
IMI2-2017-12-06 Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases

ADAPT-SMART | Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890

01-07-2015

-

30-04-2018

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.13. Other
H2020-JTI-IMI2-2015-04-two-stage
IMI2-2015-04-01 Enabling Platform on Medicines Adaptive Pathways to Patients

RHAPSODY | Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881

01-04-2016

-

30-09-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-03-two-stage
IMI2-2015-03-02 Assessing Risk and Progression of Prediabetes and Type 2 Diabetes to Enable Disease Modification

ROADMAP | Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020

01-11-2016

-

31-10-2018

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-03 Real World Outcomes Across the AD Spectrum (ROADS) to Better Care

PHAGO | Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976

01-11-2016

-

30-04-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-03 Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33

ImmUniverse | Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

01-01-2020

-

30-06-2026

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-03 Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases

TRIC-TB | Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

01-05-2019

-

29-02-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-16-single-stage
IMI2-2018-16-06 Functional Ethionamide boosters: a novel combination for tuberculosis therapy

iConsensus | Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production

01-05-2018

-

31-10-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-10-two-stage
IMI2-2016-10-05 Biomanufacturing 2020: Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes

KRONO | Evaluation of a production ready portable, Point-of-Need Platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection.

01-09-2020

-

30-06-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2020-21-single-stage
IMI2-2020-21-01

INNODIA HARVEST | Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA

01-05-2020

-

30-04-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2019-19-single-stage
IMI2-2019-19-01 Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities

BIOMAP | Biomarkers in Atopic Dermatitis and Psoriasis

01-04-2019

-

31-03-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease

TransBioLine | Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

01-02-2019

-

31-01-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-11 Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

GetReal Initiative | The GetReal Initiative

01-06-2018

-

30-04-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-11-single-stage
IMI2-2017-11-01 Exploitation of IMI project results

PD-MIND | Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

01-05-2019

-

30-04-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases

EFOEUPATI | Ensuring the future of EUPATI beyond 2020

01-09-2018

-

30-09-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-11-single-stage
IMI2-2017-11-01 Exploitation of IMI project results
Powered by Chris Decubber BV